title: Blunted response to systemic nitric oxide synthase inhibition in the cerebral circulation of patients with Type 2 diabetes.
abstract: OBJECTIVE
  Diabetes is a major risk factor for stroke, but the mechanisms that impart the excess risk are unclear. Endothelial dysfunction, which has been demonstrated in the coronary and peripheral vasculature of diabetic patients, is an important early marker of vascular disease. However, the effect of diabetes on cerebrovascular endothelium has not been examined. We sought to investigate the effect of diabetes on basal cerebrovascular endothelial function as assessed by response to the nitric oxide synthase (NOS) inhibitor NG-monomethyl-L-arginine (L-NMMA).
  
  
  METHODS
  Fourteen men with Type 2 diabetes and 15 age-matched male control subjects were recruited. The participants had no clinically evident vascular disease and were taking no vasoactive or lipid-lowering medication. Each received a single 15-min intravenous infusion of L-NMMA (0.8 mol/kg/min). Cerebral blood flow was assessed by colour Doppler imaging of the internal carotid artery (ICA) at 10-min intervals for 20 min prior to and following the infusion. Middle cerebral artery velocity (MCAv) was assessed by transtemporal Doppler ultrasound at the same time points.
  
  
  RESULTS
  L-NMMA produced a mean reduction in ICA flow area under curve (AUC) in the control group of 12.8 +/- 17.8% compared with a 2.1 +/- 21.7% reduction in the group with diabetes (P < 0.05), indicating blunted basal cerebrovascular response to NOS inhibition in the diabetic group. There was no significant change in MCAv following L-NMMA in either group. Mean +/- sd MAP rose 6.4 +/- 4.2 mmHg in the control group vs. 8.8 +/- 3.5 mmHg in the diabetic group [P = not significant (NS)]. No adverse event or symptom was reported.
  
  
  CONCLUSIONS
  Response to NOS inhibition is impaired in the cerebral circulation of patients with diabetes. This observation is consistent with the elevated cerebrovascular risk reported in this population, and may represent a future therapeutic target in stroke prevention.
authors.affiliation: Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
authors.forename: F S
authors.initials: FS
authors.lastname: Nazir
authors.forename: M
authors.initials: M
authors.lastname: Alem
authors.forename: M
authors.initials: M
authors.lastname: Small
authors.forename: J M C
authors.initials: JM
authors.lastname: Connell
authors.forename: K R
authors.initials: KR
authors.lastname: Lees
authors.forename: M R
authors.initials: MR
authors.lastname: Walters
authors.forename: S J
authors.initials: SJ
authors.lastname: Cleland
mesh_terms: D000328:Adult; D019540:Area Under Curve; D002339:Carotid Arteries / Q000000981:diagnostic imaging / Q000503:physiopathology*; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D012039:Regional Blood Flow / Q000187:drug effects; D012306:Risk; D020521:Stroke / Q000209:etiology; D017585:Ultrasonography, Doppler, Transcranial / Q000187:drug effects; D019323:omega-N-Methylarginine / Q000494:pharmacology*
chemical_list: D019323:omega-N-Methylarginine; D019001:Nitric Oxide Synthase